Vitamin K Antagonists: Mechanism and Usage

CHAPTER 1:

The biological mechanism of resistance to vitamin K antagonists:

The antagonists of Vitamin K (VKA) acts as inhibitors for the physiological mechanism of regeneration cycle of vitamin K. The reduction of the accessible and usable forms of vitamin K in the body initiated by VKA drives in a roundabout way to a “hypocoagulable” condition of the blood. In case of the human beings, the VKA anticoagulants are utilized to forestall venous and blood vessel thrombotic occasion. Despite the expanding utilization of newer orally administered anticoagulants, VKA and, all the more definitely, warfarin are the most usually recommended anticoagulants [1]. It was evident that among peoples, VKA anticoagulants demonstrate a restricted range for treatment purpose [2]. However, below and excess dosage might exhibit severe results by the absence of adequacy or unfriendly occasion. It must be taken into consideration that warfarin is considered to be positioned at number 9 among essential presume drugs demonstrating severe contraindications in the United States during the initiation of the decade of the year, 2000 [3]. Therefore, surely, the dosage of VKA must be modulated, mirroring the genotype of patients in comparison to remaining varied normal medications. In this way, it is important to recognize and portray every hereditary units and any kind of mutation which may impact the dosage of VKA.

Regeneration Cycle of Vitamin K:

Notwithstanding the reduced level of vitamin K within the food, the insufficiency of this particular nutrient in our body is found to be uncommon [4]. In reality, the recycling process of vitamin K is carried out by the cells of our body. The cycle is made out of two extraordinary advances: the GGCX enzyme protein utilizes the vitamin K hydro‐quinone to initiate VKDPs and the second step is the recovery or re production of the vitamin K hydroquinone from the epoxide structure by VKORC1 enzyme (Refer Figure 1). During the procedure to chelate the calcium ions in order to be dynamic, the glutamate remains (Glu) of VKDPs must be carboxylated to Carboxyglutamic Acid (Gla). This chemical equation is intervened by Gamma-Glutamyl Carboxylase (GGCX) enzyme. GGCX perceives the VKDPs with the assistance of their propeptide [5, 6]. At that point, GGCX eliminates the hydrogen attached at the gamma position of Glu deposits and includes CO2 which results in the oxidation of vitamin K hydroquinone (KH2 ) and coverts it to vitamin K epoxide (K > 0) and in the process releases the necessary vitalities [7]. This chemical phenomenon occurs at site of the intracellular organelle endoplasmic reticulum [8].

Different categories of Vitamin K antagonists (VKA):

The VKA was evident to be found for the first time in the year of 1941 and afterward it had been extracted from the fouled sweet clover by Hueber and Link [9]. It was discovered that sweet clover known by the scientific name Melilotus officinalis posesses the bioactive metabolite named coumarin. It was observed that within an ineffectively safeguarded silage or roughage, this “coumarin” can be converted to form named “dicoumarol” with the aid of mold Penicillium species generally found to inhabit within the soil [10, 11]. The chemical compound dicoumarol present within in fowled left over medium or waste eventually results in the development of hemorrhagic or blood loss condition called sweet clover illness. A few years after this revelation, Coumadin, a manufactured VKA also being referred as warfarin, was orchestrated [12]. This particular last synthesized chemical compound is as yet the most regularly recommended anticoagulant as evident from the existing scientific evidences. There are 3 varied VKA families which are utilized: the 4-hydroxy-thiocoumarin derivatives, the 4-hydroxycoumarin derivatives and the indane-1, 3-dione derivatives (Refer Figure 2). With regard to the application within medication regimen for treatment of human beings, just the derivatives of 4-hydroxycoumarin for instance, warfarin and the derivatives of indane-1, 3-dione for instance, fluindione are taken into consideration [13].

Anticoagulant Warfarin:

The oral anticoagulant, Warfarin (Coumadin) is most every now and again used to control and forestall the thromboembolic events. In this regard, recommending of the accurate dosage that assists both in the process of inhibiting hemorrhagic complexities and accomplishes adequate concealment of the events of thrombosis requires a careful comprehension of the medication's pharmacology and pharmacokinetics. The medication, warfarin is evident to demonstrate an intricate reaction to dosage relationship that makes the secured and successful utilization of the drug a difficult task. For most of the signs, the drug dosage is changed in accordance with keep up the patient's International Normalized Ratio (INR) within 2 - 3. In light of the postponement in factor II also known as prothrombin concealment, another anticoagulant heparin is applied simultaneously for 4 to 5 days to forestall endangering blood clot formation. However, the administering dosages of warfarin are not justified and may bring about the complications of haemorrhage or blood loss. Therefore, in this regard the contraindications with different medications must be thought of, and treatment of older patients demands cautious administration. Current dosing proposals are constantly evaluated, and reasonable rules for the ideal utilization of warfarin are also mentioned in varied scientific eveidences. However, in the year, 1995 the Agency for Health-care Policy and Research (AHCPR) [14] revealed that the drug warfarin is extraordinarily used below the expected level for the prevention of stroke. It was also observed by the AHCPR that doctors are hesitant to endorse warfarin, to a limited extent since they are inexperienced with procedures for managing the medication securely and dread that the medication will eventually cause haemorrhagic complications. So it is advised that patients administered with anticoagulant warfarin necessitate close observation to abstain from blood loss, however it has been demonstrated that the medication forestalls 20 strokes for every blood loss scene that it demonstrates [15].

The action mechanism of VKA:

The antagonists of vitamin K hinder the mechanism of recycling of the micro nutrient vitamin with the aid of non competitive inhibition of the enzyme protein VKORC1 [51, 52]. However, in the field of research, the interaction or the bonding of the enzyme VKORC1 with VKA chemical is as yet a hazy area and needs profound research to accurate portray the mechanism. The coupling reversibility of the enzyme and the chemical is still by and large obscure [16 - 18], just as the coupling site. In the first place, the coupling site has been situated at the base of the TYA moiety (the range of the residue from 138–140 within human VKORC1) which is near to the active site of CXXC. Without a doubt, the variation caused due to the mutation of the 139 tyrosine nucleotide of the moiety is related with resistance developed against warfarin among people [19, 20], and in this regard it must be mentioned that by similarity the coupling site of dicoumarol located at NQO1 is additionally a TYA moiety [21]. Nonetheless, these transformations are showing tolerable vulnerability to second categorizations of VKAs among study models of rodents [22, 23], which is acting as an indications to recommend that other or varied types of amino acids may be engaged within the process of bonding. As of late, the author, Czogalla et al. have hypothesized a model that incorporates three interfaces for the bonding among warfarin and the VKORC1 enzyme of human origin [24].

The Vitamin K Antagonist (VKA) elimination pathway:

The therapeutic aspects with VKA medicines are usually continued for a long period of time. Subsequently, their disposal from our physiological system is considered to be a key parameter which decides their accumulation or retention within the hepatic system and lastly their productivity observed as the outcome of the treatment. The pathway of elimination appears to rely upon the molecular structure and also on its enantiomeric structure. However, the enantiomeric froms of warfarin are wiped out from our physiological system in a different mechanism. In this regard, it should be mentioned that the metabolism of (S) - enantiomer is carried out only by the hepatic cytochrome P450 isoform 2C9 (CYP2C9), whereas the metabolism of (R)- enantiomer is processed by isoforms CYP2C19, CYP3A, CYP1A2 and hepatic ketoreductase [25, 26]. Despite the fact that the (R) - enantiomer exhibits a more extended half-life, it is found to be less efficacious, and also with the alteration of its disposal pathway has no noteworthy effect on the process of coagulation [27- 29]. Interestingly, the CYP2C9 activity is considered to be crucial and basic regarding the assurance of the dosage of warfarin. Moreover, the action of CYP2C9 is affected by many medication cooperations [30–32], and CYP2C9 polymorphism can also likewise regulate the affectability to warfarin.

Evaluation of the resistance observed:

From the time of disclosure of the fact that rodent model are impervious or showing resistant to warfarin as observed by Boyle in the year, 1960 [33], the evaluation and the investigation of the mechanism of resistance have been considered as the primary issue with regard to the management and dosage of human medication. Numerous strategies had been pursued by varied researchers to contemplate these pathways leading to development of resistance. Their motivation is to seclude the potential causes of the resistance development in a normalized model and thereafter to assess if the actuated factor for resistance is of a similar mechanism as that one viewed in the in vivo condition. The “resistance factor” is the parameter with which the concentration or dosage of VKA necessitated for a vulnerable populace should be duplicated to accomplish a similar impact inside a populace showing the attribute of resistance [13].

Study with Pharmacogenomics:

The varied investigation on the pharmacogenomics considers are the primary resources of the experimentation carried out in vivo models with regard to the resistance developed against VKA among people. These investigations survey the relationship between the hereditary parameters of the subject population and the dosage of warfarin, which permits to keep the International Normalised Ratio (INR) of patient within the desired range. The polymorphisms observed among the CYP2C9 and the VKORC1genotypes are considered to be major factors. Be that as it may, there are numerous different parameters, which may impact upon the susceptibility of VKA, which are considered to be obscure and could not be assessed by these examinations. The investigations based on pharmacogenomics surveys the study of prevalence of mutations or polymorphisms in connection to the development of resistance and this can help in the assurance with regard to introductory dosage for the treatment by assessing the genotype of the patient involved. Yet, their commitment to the investigation concerning the pathway of resistance development is restricted to the affirmation or not of the outcomes acquired with different strategies [13]. In the present assignment the details about the polymorphism observed within the human genotypes of VKORC1 is taken into consideration along with the associated resistances observed.

CHAPTER 2:

Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) gene

The particular gene VKORC1 is situated on the 16p11.2 locus of the chromosome and its significance was discovered with respect to the resistance developed against “warfarin”. The gene codes for a protein comprising of 163 amino acids and it is evident to be an integral membrane protein of endoplasmic reticulum. Warfarin is the most commonly prescribed anticoagulant and high dosage of warfarin (for instance >20 mg/day) was utilised to achieve the degree of anticoagulation required for the treatment purpose. The gene VKORC1 is responsible for the production of the intricate sub factor of the enzyme named vitamin K epoxide reductase which is considered to be the target of anticoagulant warfarin and it performs the key role in the cycling of vitamin K. The anticoagulant targets the enzyme catalyzed step or the rate limiting step of the vitamin K cycle and helps in the γ carboxylational step after translation to synthesize the essential clotting factors such as II, VII, IX, X and proteins S and C. The essential production site of the VKORC1 enzyme is within the hepatic organ system but it also expressed within other varied types of tissues. The enzyme is abundantly present at the membrane border of the intracellular organelle endoplasmic reticulum that is responsible for the processing and transporting of protein. Therefore, the essential responsibility of the enzyme coded by the gene VKORC1 is the activation of the clotting factors within the pathway of blood clot formation. It must be noted essentially that the VKORC1 coded enzyme is responsible for the conversion of one form of vitamin K epoxide into the other forms of vitamins that which helps in the stimulation of protein usually assists in the mechanism of blood clotting [34].

Associated resistances to VKOR:

The contemplate findings on pharmacogenomics and the data of disappointments due to failure of therapy with warfarin have particularly indicated regarding two sorts of polymorphisms connected to VKORC1 which impact the necessities of dosage of warfarin. The first observed variation is connected to the polymorphism observed in the noncoding sequences of the gene (intron) while the second is connected to variations known as “missense mutations”. The polymorphism which is observed within the noncoding sequences is considered to be the source of maximum variations with regard to the dosage of varied types of VKA [35- 38]. In fact, the noncoding locale impacts the level of transcription of VKORC1 gene [37]. However, it was also evident that these differences are considered to be insignificant, not many milligrams of increment or lessening with respect to the dosage of VKA. Along these lines, therefore, it should be mentioned that the mutations are not responsible for the resistance development but generally alteration of the dosage of VKA showing susceptibility. On the other hand, the variations due to mutation within the VKORC1 coding sequences are uncommon, whereas some contributes to a genuine development of resistance against VKA. They are portrayed by the varied dosage utilized to balance out the process of anticoagulation, which is comparatively high than the highest threshold edge characterized by Watzka for instance warfarin (W) (7.1 mg per day), phenprocoumon (3.0 mg per day), fluindione (19.8 mg per day) and acenocoumarol (3.5 mg per day) for mean of the age variable of subjects undertaken for the investigation [21]. It should be also taken into consideration that the accurate definition of resistance to warfarin is not yet formulated. As of now, there are in excess of 27 variations or mutations that have been portrayed among varied patients demonstrating high necessities of VKA portion. They are summed up in Table 1.

On the other hand, another variation attributed due to mutations had been portrayed by Rost within two families originating from Libya, namely the R98W mutation. Patients with homozygous condition possessing the particular variation demonstrate a consolidated inadequacy of coagulating factor type 2 dependent on vitamin K- which eventually results in bleeding or haemorrhage [39]. This insufficiency can be healed via the daily dosage of vitamin K. Moreover, Rost et al. in his study had demonstrated via enzymatic measures that VKORC1 comprising of R98W-mutation, when expressed within Human Embryonic Kidney (HEK) cells, exhibited the decreased activity of VKOR by about 90% [39]. It was also evident from varied scientific evidences that few mutations exhibit a comparatively higher predominance within certain populaces. In this way, the D36Y variation is generally very much prevalent among some populaces within African continent [40]. Interestingly, it should be noted that the Ashkenazi Jews populace and the Ethiopian populace usually demonstrates the recurrence of D36Y allele separately within 4% and 15% [41–43], whereas this particular change is considered to be missing within Chinese or in South African populaces [44, 45]. Moreover, the mutation of V66M, was found to be depicted among African and African-plunge populaces [46–48]. Ultimately, the mutation of L128R had been portrayed among various families [39, 49]. However, the other revealed transformations have been depicted just one time and some of the time with respect to tolerance for unsteady anticoagulation process. These components lessen the potential outcomes to decide an obstruction factor for each. Additionally, the changes have been regularly depicted as accidental occasions within the studies of pharmacogenomics [40]. At last, the collaborations with different variations due to mutations on GGCX, cytochromes, or noncoding part of VKORC1 hereditary sequences can likewise adjust the dosage of warfarin and in turn improve or lessen the development of resistance. In this way, the appraisal of these transformations just from case report involves a great deal of predisposition. So as to manage the portrayed predisposition, the in vitro outcomes can be considered to be valuable. The in vitro outcomes from enzymology [50] and cell culture based measures [40] have been accounted in details within Table 1 (Refer Table 1). However, all variations do not appear to be related with resistances evaluated via in vitro experimentations. Interestingly it must be mentioned that only study conducted by Oldenburg had mentioned that all the mutations within VKORC1 coding sequences were found to be resistant in nature assayed via cell culture based protocol; however his findings were not revealed within the table [51]. This inconsistency between measures may be because of the VKORC1L1 hereditary sequences as up to clarify in the portrayal of the cell culture based examines. In addition to this, the examinations based on enzymology indicated that a few changes abruptly reduce the action of VKOR enzyme [51], while cell culture based measures do not show such indications [40]. The investigation with regard to the paralog mutations among model of rodents may assist with understanding the genuine effect of these transformations on the development of resistance.

The polymorphism observed within the gene sequence of the VKORC1 is basically referred as the Single Nucleotide Polymorphism (SNP) of the position rs9923231 (1639 G>A; G3673A) that results in the alteration of the binding site of the transcription factor within the promoter region of gene VKORC1 along with 1639A that in turn resulted in reduced expression of the mentioned gene. The expression of genetic factor VKORC1 is evident to be under the regulation of epigenetic factors. Depending on the findings of the in vitro experiments which states that the micro-RNA miR-133a of the hepatic system cooperates with the 3' untranslated regions (UTR) of messenger RNA (mRNA) of VKORC1 and reduces the mRNA expression via the dose dependent mechanism of VKORC1 gene whereas with regard to the ex vivo samples of the liver extracted from healthy subjects the expression of mirR-133a is in reverse association with the mRNA levels of the VKORC1 gene. It has been observed that the production of diminished amounts of vitamin K is considered to be significantly important for varied co-factors which are required at the time of clotting such as factor VII, IX and X. The interest for treatment of the gene is due to its role of involvement within the observed high variability among inter patient with regard to the dosage demands of the anticoagulant coumarin and also because of the significant role in case of vitamin K deficiency disorders. Warfarin is a regularly endorsed, administered orally anticoagulant used to forestall thromboembolic ailments among patients with atrial fibrillation, profound vein thrombosis, intermittent stroke or heart valve prosthesis [6]. Warfarin, just like the other similar coumarin-category drugs with comparative activity pathway or action mechanism, performs the activity as an inhibitor of VKORC1 gene expression. This overall mechanism prompts a decreased measure of nutrient K accessible to fill in as a cofactor for coagulating proteins [1]. However, it has been also observed that the successful dosing of warfarin was becoming a difficult task because of its low spectrum index of treatment and high level of inter individual changeability with regard to ideal dosing (somewhere in the range of 0.6 and 15.5 mg/day) [7–10]. Wrong dosing of warfarin has been related with a generous danger of both major and minor blood loss or hemorrhage [6,10,11]. Warfarin acts as the pharmacological objective; therefore, VKORC1 is viewed as the prospective sequence to study the inconsistency in warfarin reaction. Numerous investigations that have endeavoured to clarify the components that impact reaction of warfarin [6,12,13]. Before the cloning and eventual portrayal of VKORC1 gene, it was thought that the genotype CYP2C9 of patients assumed a function with regard to digestion of warfarin and reaction. It was based on the observation of genotype CYP2C9 within patients clarified that around 10% of the watched changeability in the treatment index of dosage of warfarin [14]. In the year 2004, the gene sequence of VKORC1 was cloned by two unique investigating gatherings, and a few variations within the sequence responsible for presented resistance to warfarin were depicted [1,2]. The resulting assessment of other VKORC1 variations has demonstrated that polymorphisms in the VKORC1 hereditary sequences were related with both elevated and reduced dosage of warfarin phenotypes among people. Therefore, generally, polymorphisms within the VKORC1 represent around 25% of the fluctuation with regard to dose of warfarin and numerous examinations have reliably demonstrated that VKORC1 genotype is by all accounts for the single greatest indicator of dose of warfarin [13,15 –17]. Among the other, non hereditary factors which include sex, age, mass of the body, weight, and international normalized ratio are additionally known to assume a job in warfarin reaction and on the whole add to roughly 20% of difference in the dosing. In addition to these, at the year 2007, the information based on genetic sequence for pharmacology for warfarin was affirmed by Food and Drug Administration to be remembered within the labelling for the item name expressing that VKORC1 and CYP2C9 genotypes might be valuable in deciding the ideal introductory dosing of warfarin [20]. Therefore, in this regard a huge number of clinical studies based on randomised control trials were going on with an aim to formulate an utilizable strategy for dosing of warfarin throughout the globe.

Function of Vitamin K in human physiological system:

The nomenclature of the vitamin K originates from the German word "koagulation". It was evident that with the lacking of vitamin K, a symptomatic manifestation of bleeding was observed which led to the discovery of the significance of vitamin K [4]. However, it is just during the 1970s that several researchers or biologists started to comprehend the working mechanism pathway of vitamin K within our system. Vitamin K acts as a cofactor after the transcriptional gamma-carboxylation which initiates Vitamin K Dependent Proteins (VKDP) [14]. There are four factors related to clotting within the cascade of coagulation are the VKDPs, factors II, VII, IX, and X, which clarify the issues of bleeding observed if there should arise an occurrence of inadequacy. Proteins S, C and Z are likewise VKDPs engaged with coagulation process, yet they have an antithrombotic impact. All things considered, the principle impact of VKA is anticoagulation, despite the fact that the quick diminishing of these molecules necessary for antithrombotic action can prompt a transient hypercoagulable state toward the start or towards the finish of the therapy with conceivable unfriendly reactions [15, 16]. The second incredible job of the vitamin K is interaction with two VKDPs: osteocalcin and lattice GLA protein [17, 18]. This last protein is additionally associated with the assurance against the physiological mechanism of tissue calcification [19]. Moreover, vitamin K is associated with numerous other biological reactions as evident in varied scientific evidences [20, 21].

Genetic variations within VKORC1 sequence:

A few investigations in autonomous populaces have demonstrated the significance of variation hereditary sequence in VKORC1, and a couple of significant polymorphisms and haplotypes have been characterized [9, 21, 22]. In the areas that follow, we sum up the significance of three of the most widely recognized and very much contemplated VKORC1 polymorphisms.

The important mutations or polymorphisms within the gene sequence of VKORC1:

VKORC1: G3673A (rs9923231)

VKORC1: C6484T (rs9934438)

VKORC1: G9041A (rs7294)

VKORC1: G3673A (rs9923231)

G3673A, or – 1639 G > A as it is usually referred in the evidences or biological scientific communications, is a polymorphism with the sequence of the promoter division of gene VKORC1 that is accepted to be the causative single nucleotide polymorphism (SNP) with regard to the diminished dosage phenotype. This variation or mutation modifies the binding site of the factors of transcription of the VKORC1 gene and with the aid of luciferase expression measurement showing that the action of the G allele is expanded by 44% over the expression of the A allele [26]. Also, investigation of VKORC1 mRNA extracted from human hepatic tissues indicated that A allele carriers at the position of 3673 have exhibited diminished measures of VKORC1 mRNA [9]. Eventually due to the adjustments in genetic sequence expression probably lead to less synthesis of the fully develop VKORC1 protein, which is the enzyme essential for the rate-limiting reaction within the vitamin K cycle. The G3673A or – 1639 G > A variation had been observed within the gene sequence among various populaces. It was evident based on several literatures that this polymorphism has articulated contrasts in its recurrence within the ethnic gatherings. It is really the greater part allele observed (nearly 90%) among the Asian populaces and appears to clarify the lower dosage of warfarin necessity for people of Asian source. Moreover, this particular variation is additionally very normal within Caucasians, with an allele recurrence ordinarily around 40% in overwhelmingly Caucasian populaces. The widespread finding with this variation is that bearers of the “A allele” react to a lower introductory portion of warfarin in comparison with the carriers of the G allele [34]. It should be noticed that this impact is considered to be summative in nature, and that the population heterozygous in genotype react to a moderate dosage of warfarin, and those are in homozygous condition with respect to the An allele react to the least dosage of warfarin and are at the most noteworthy hazard risk for any warfarin-related unfriendly reactions [9]. Late clinical investigations indicated that people with genotype containing the A allele requires a 28% reduction in the restorative warfarin dosage per allele and this SNP is the most significant indicator of the commencement dosage of warfarin [19].

VKORC1: C6484T (rs9934438)

C6484T, or 1173C > T, is a variation due to the single nucleotide polymorphism within the first intron sequence (that do not encodes protein) of VKORC1. It is in close to consummate linkage disequilibrium with position G3673A. C6484T was fund to be the primary SNP which is related with the reduced dosage of warfarin phenotype [23], and in spite of the fact that it is accepted to be practically latent or inert, C6484T is still regularly utilized as a marker SNP for G3673A and for the haplotypes which comprises this variation.

VKORC1: G9041A (rs7294)

G9041A, or 3730 G > A, is found to be another SNP in the 3′UTR sequence of VKORC1, and it might be related with a higher dosage of warfarin [23,27]. Moreover, it is also evident that it cannot be commonly be found in the equivalent haplo-types such as G3673A or C6484T. There are various endeavours in varied scientific communications to characterize the structure of VKORC1 haplotype. However, the frameworks concur that haplotypes containing the G3730A variation are with diminished capacity haplotypes of VKORC1, however the classification is fluctuated. Within the detailed VKORC1 VIP report, an exertion is made to recognize the current kinds of haplotype terminology and to depict what impact every haplotype has on treatment procedure with warfarin.

Overall as the summative analysis, VKORC1 polymorphisms can fundamentally change the pharmacodynamics of warfarin and support dosage prerequisite. Patients possessing the 1639A (rs992323) and 1173T (rs9934438) allele necessitate a lower dosage of warfarin (mean value of dose 24–26 mg/week) when contrasted with 35 mg/week for the wild-type bearers [28]. Moreover, patients possessing 9041A (rs7294) necessitate a large dosage of warfarin (mean value of the dosage is 40 mg/week) [27,28]. Combined findings on VKORC1 and CYP2C9 genotype and clinical factors, for example, age and weight when incorporated into the equation of warfarin dosing holds extraordinary guarantee to choose the ideal dosage for the individual patient toward the beginning of treatment with warfarin.

The variation of the gene among various populaces:

A study was conducted among the subjects of the Ghanaian population to estimate the frequency of variation of the VKORC1, CYP2C9 and CYP4F2 alleles and also to determine the impact of these variations or polymorphisms on the warfarin keeping up dosages. In addition to these objectives, the study also aimed to document the demographic and clinical parameters that are related to the warfarin dosage among the aboriginal Ghanian patient populations. The investigation incorporated about 143 subject populace of Ghanian origin who were on steady warfarin treatment. The patient were obtained from Korle-Bu Teaching Hospital and they undergone the genotyping for CYP4F2 rs2108622, CYP2C9 (*2, *3) and VKORC1_1639G > A polymorphisms with the aid of Polymerase Chain Reaction followed by Restriction Fragment Length Polymorphism (PCR – RFLP) assay protocol. The study highlighted about the inclusion criteria for the patients who were undertaking the warfarin therapy were replacement of valves (N = 63 or 44%); deep vein thrombosis (N = 52 or 36.4%); atrial fibrillation (N = 10 or 7.0%) and pulmonary embolism (n = 18 or 12.6%). The study findings of the investigation highlighted that there was a inverse or negative correlation between the age of the patients and the dosage of warfarin. However, the study findings were not statistically significant demonstrating (r = -0.024, 95% Confidence Interval (-0.052-0.004), p = 0.090). The study also highlighted about the women who were undertaking large dosage of warfarin of mean value 5.75mg (95% CI, 5.174-6.326) whereas on the contrary men were under taking comparatively lower doses of warfarin of the dosage mean value of 5.46 mg (95% CI, 4.907-6.022). However, the researchers also suggested that these variations were not statistically significant with p value within 0.479. The study findings also highlighted that the dosage of the warfarin had a positive association with the height of the patient but the parameter of BMI did not have any impact upon the dosage requirement of warfarin. These demographic factors as such did not show any statitistical validation [52]. The frequency of allelic variations for CYP2C9*3 were seen at 23% whereas the frequencies for genotype CYP2C9*3 were seen to be at 10.87%. Moreover, CYP2C9*2 alleles and genotypes were not identified in this investigation populace. The study findings also focused that the frequencies of allele for VKORC1-1639A were seen to be at 6%, on the contrary, the genotype VKORC1-1639A was not distinguished in this examination. Another point to consider that frequencies of allele for CYP4F2 rs2108622 (T) was seen to be at 41% along with its frequencies for genotype (T/T) were found to be at 6.84%. As per the cumulative impact of the varied genotypes namely VKORC1, CYP2C9 and CYP4F2, patients possessing the wild-type (*1/*1) genotype of CYP2C9 in blending condition with the homozygous variation (T/T) genotype of CYP4F2 along with the wild-type (G/G) genotype of VKORC1 necessitated the most noteworthy mean every day dosage of warfarin at value 7.50mg/day with statistical significance of 95% CI, 7.50-7.50, p = 0.096. Moreover, the result of the study additionally highlighted that patients with a mix of CYP4F2 wild-type (C/C), CYP2C9 wild-type (*1/*1) and VKORC1 wild-type (G/G) genotypes received the therapeutic dose with the most reduced mean dosage for every day of warfarin of value 4.79mg/day with statistical significance of 95% CI, 3.02-6.55, p = 0.096. Strangely, populace who were bearing the heterozygous genotypic condition of CYP4F2 (C/T), CYP2C9*1/*3 and VKORC1 wild-type (G/G) were administered with 6.50mg dosage with statistical validation of 95% CI, 5.40-7.60, p = 0.027. Therefore, it must be mentioned as reported by the researchers that this investigation has set up for the first time the joined impact of genotypes of VKORC1, CYP2C9 and CYP4F2 hereditary factors on mean day to day dosage of warfarin among the Ghanaian patients. Moreover, the researchers also stated that CYP4F2 and VKORC1variations within alleles as far as anyone is concerned are being accounted for the first time among the aboriginal populace of Ghana [52]. Similarly another study was conducted by a group of researchers to study or investigate the prevalence of ethnic differences for the polymorphism observed within the gene VKORC1 and also to examine the association between the variations with the required dosage of anticoagulant warfarin for the focus group population of cardiac surgery patients. As because there are numerous cases which focuses on the hospital admission due to drug warfarin and this situation demands an urgent necessity for developing experimental study with regard to upgraded prescription of warfarin. The study findings essentially highlighted about the dissemination of polymorphism within the protein non coding sequence (intron) 1 -136 T>C (1173 T>C intron) which was previously reported among varied scientific evidences in association with different dosage of warfarin and its maintenance among widely different ethnic populaces such as among Japanese and Caucasians, among the sample populace of Israel. The particular investigation also discussed about the importance of dosage of warfarin among the populace patients of Japan who had undergone cardiovascular surgical procedures. The researchers of the investigation included sample populace from different background for instance 132 individuals from Japan, 341 individuals from Israel and subjects from 4 different ethnic groups of Jewish which comprised of 95 Yemenite Jews, 86 Ashkenazi Jews, 87 Libyan Jews and 73 Moroccan Jews. Moreover, in addition to this subject population, the study included another 31 patients from Japan who were undertaking the therapy of warfarin after the cardiac surgical procedures and as maintained according to the objectives of International Normalized Ratio. The methodology adopted for the investigation of polymorphism of VKORC1 gene within the genotype 1173 T>C intron was the rapid testing by the real time PCR assay standard protocol. The study findings highlighted that by and large, the frequency of allele for the cumulative genotypes of VKORC1 1173 CC and CT widely differed among the four different ethnic groups of Israel and it was a lot higher among the Israel populace of 0.728 than in comparison to the Japanese populace of 0.152. However, with regard to the Japanese patients who had undergone the cardiovascular medical procedures, the up keeping dosage of warfarin was found to be profoundly large within the joined VKORC1 1173 CC and TC genotype populace in comparison to the group comprising of genotype 1173 TT with statistical validation of 3.6 ± 0.5 mg versus 2.8 ± 0.7 mg, individually with p value of 0.02. Therefore, ultimately the researchers concluded that the recurrence of the intron 1 VKORC1 1173 T>C SNP show critical contrasts between ethnic gatherings and are related with dosage of warfarin prerequisites for accomplishing a suggested International Normalized Ratio extend within the Japanese patients undergone the medical procedures of heart. Therefore, this examination bolsters the case of warfarin as a suitable model for applying customized medication as an anticoagulant medication, and features the significance of ethnicity in the field of pharmacogenetics [55]. In this regard another study was aimed to investigate the impact of anticoagulation of warfarin in relation to certain genes such as Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1), Cytochrome P450 complex subunit 2C9 (CYP2C9), Apolipoprotein E (APOE) and Gamma-Glutamyl Carboxylase (GGCX) etc. This study was a systematic review along with meta analysis conducted by a group of researchers to explore the correlation between the mean value of the daily dosage of warfarin referred as (MDWD) and the SNP of VKORC1 gene. With regard to the inclusion and exclusion criteria as mentioned by the researchers of the study highlighted that overall the scientific evidences since the year 2004 to 2010 were taken into consideration for the systematic audit. After the screening of the most relevant studies, the findings of the investigations were extracted and the association in between the two factors MDWD and the SNP of VKORC1 gene were examined with the aid of Revman 4.2.10 software [54]. Among the studies screened the concentrated 19 investigations were remembered for the meta-examination. The repetition of the genotypes 1639 AA and 1173TT among the patients of Asian origin were comparatively higher in comparison to those African and Caucasian populaces. It was noted that patients possessing the VKORC1 1173 CC and 1173 CT genotypes necessitated about 97% (73%, 122%) and 44% with statistical validation of 95% of CI; (32%, 56%) larger MDWD when compared with 1173 TT bearers, 1639GG and 1639GA carrying populace demands 52% (41%, 64%) and 102% (85%, 118%) larger MDWD than - 1639AA bearers, 3730GA and 3730AA bearers required 27% (3%, 58%) and 52% (3%, 109%) larger MDWD than 3730GG bearers. Likewise, 1173C, 3730 A and - 1639 G possessing populace demanded 63% (44%, 82%), 61% (49%, 73%) and 32% (4%, 59%) higher MDWD in comparison to - 1639 AA, 3730GG, and 1173TT separately. Examinations were carried out to analyse the sensitivity showed that the effects of polymorphism of hereditary units on dosage measurement and necessity of warfarin were essentially distinguished among the populace of Asian and Caucasian origin, and due to which the consequences of meta-investigations were steady and solid. The researchers of the study concluded that that was the first meta-investigation about the effect of VKORC1 hereditary unit polymorphism on dosage necessity of warfarin. Their examinations demonstrated that quality polymorphisms of VKORC1 altogether connected with the variety of inter individual warfarin dosage necessity, and the impacts are distinctive among ethnicities [53]. Similarly several other researchers from varied points of time and globe have tried to establish the connection between the single nucleotide polymorphism of C to T within the hereditary sequence of 1173 nucleotide of VKORC1 and its possible association with the dosage requirements of warfarin. It is evident based on varied scientific communications that those patients with the genotype CC demanded about 7 mg of average warfarin on every day basis that was found to be comparatively much high with respect to the dosage requirements by the CT genotypes (5.1 mg every day) and those individuals with possessing the TT genotypes necessitating about 3.7 mg every day. A researcher from China Yuan et al. highlighted within his investigation about the SNP of G to A within the promoter sequence of VKORC1 gene and its association with sensitivity to anticoagulant warfarin among the patients of China. It stated that those patients with the phenotype AA were demonstrating lower necessity of warfarin approximately 2.61 mg / day in comparison to the group of patients possessing the G allele with dosage demand of 3.81mg / day. In addition to these information, those patients who possessed the variant CYP2C9 allele demonstrate a lower dosage demand of warfarin of about 27%. The polymorphism of the VKORC1 gene was calculated to be nearly twenty five percent of the variance observed among the inter individuals with respect to the warfarin dosage requirements and in addition to this another 10% was attributed for the polymorphism within the CYP2C9 allele. However, it must be mentioned that according to the existing scientific evidences, the left out variation of 65% with regard to the dosage of warfarin was considered to be beyond illustration. The other factors namely the Gamma Glutamyl Carboxylase (GGCX), the enzyme protein which utilizes vitamin K for the stimulation of varied coagulation factors and genotype such as Apolipoprotein E4 genotype those are evident to be incorporated within the dietary absorption physiological pathway of vitamin K, although there were limited information available on this topic were concerned for this cause. It was also evident based on the ethnic differences among the inter group populations the dosage requirements of the warfarin has a strong correlation with hereditary information. The mean value of the dosage administered every week of warfarin varies in between 24 mg every week for the Asian Americans, 31 mg every week for Hispanics and 36 mg every week for the Caucasians and 43 mg every week for African Americans with the statistical validation of p value showing < 0.001. Moreover, it could be also mentioned that this information appropriately matches with the recent findings on the haplotypes VKORC1 that stressed on the information for diminished requirements of warfarin evident to be common among the populace of 89% of the Asian American and less recurrent among 14% of the African American populations in comparison to the 37% of the European American populaces. Similarly, the genotype that is associated with diminished dosage of warfarin for instance the CYP2C9 allele are considered to be 5 times more frequent among the populace of Caucasians Americans which is having an allelic frequency of 0.12 – 0.22 in comparison to the populace of African American with an allelic frequency of 0.02 – 0.04. Additionally it is important to note that, the variant or polymorphism of CYP2C9 is evident to be rarely available among the populace of Hispanics and Asians, the phenomenon failed to illustrate the diminished or reduced dosing of warfarin among these studies populaces. In this regard another investigation must be discussed by a group of researchers with regard to the prevalence of polymorphism of genetic sequence of VKORC1 and CYP2CC9. The study also aimed to investigate about the suggestions of management of warfarin and its prospective outcome among the populace of Croatian patients who had undergone acute forms of stroke. The background information on the commonness of CYP2C9 and VKORC1 hereditary units along with their effect on anticoagulant impact and dosage requirements of warfarin among stroke patients populace are scarce. The objective of the investigation was to decide upon custom-made wellbeing and strength of anticoagulation reaction relying upon the allelic variations. The researchers had the objective to study their effect on the clinical result among intense stroke patients in Croatia. With regard to the methodology of the study the researchers highlighted that they had included overall sample size of one hundred and six patients of acute stroke after obtaining proper informed consent and were assayed for the genotype of VKORC1 1173C>T and CYP2C9 2, 3 gene polymorphisms. The group of researchers also calculated the dosage of the anticoagulant and monitored the impact with the aid of INR values. The other factors that were taken into consideration were the time period to reach the stable dosage, the keeping up of the stable dosage, the time frame involved within the therapeutic or sub therapeutic extension of INR, the prevalence of the contraindications of the dosage of warfarin and the outcome of the clinical experimentation based on the genotypes. The researchers highlighted within the study findings that about 83% of the patients who had suffered from stroke included within the subject population of the investigation possesses variation within multiple alleles. The mentioned introductory dosage was found to be in association with the steady up keeping dosage of warfarin having the statistical validation of p value of 0.0311. The researchers truly calculated the dosage of 81.5% of the 61.3% study subject populaces who were demonstrating the large and diminished dosage requirements in comparison to average dosage. The study also highlighted that the complications with relation to dosage of warfarin was much higher with the polymorphism observed with CYP2C9 2, 3 genotype than in comparison, to the subject population possessing the allele VKORC1 1173T. The percentage of distinction observed was 68.9% versus 62.5% with respect to the requirement of dosage of warfarin although, it was also mentioned by the researchers that their findings did not have any impact upon the final clinical outcomes of the experimentation. To conclude their study, the researchers stated that the information demonstrated quick and secure anticoagulation accomplished by utilizing pharmacogenetically-anticipated warfarin portion among high-chance intense stroke patients without expanding the danger of warfarin measurement inconveniences in an old populace [21, 29, 54 and 31].

References:

Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc Bayl Univ Med Cent. 2001;14(3):305–6.

Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167(13): 1414–9.

Pan LC, Price PA. The propeptide of rat bone gamma-carboxyglutamic acid protein shares homology with other vitamin K-dependent protein precursors. Proc Natl Acad Sci U S A. 1985;82(18):6109–13.

Stanley TB, Jin DY, Lin PJ, Stafford DW. The propeptides of the vitamin K-dependent proteins possess different affinities for the vitamin K-dependent carboxylase. J Biol Chem. 1999;274(24):16940–4.

Friedman PA, Shia MA, Gallop PM, Griep AE. Vitamin K-dependent gammacarbon-hydrogen bond cleavage and nonmandatory concurrent carboxylation of peptide-bound glutamic acid residues. Proc Natl Acad Sci U S A. 1979;76(7): 3126–9.

Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease VI. The synthesis of the δ-diketone derived from the hemorrhagic agent through alkaline degradation. J Biol Chem. 1941;138(2):529–34.

Lefebvre S, Benoit E, Lattard V. Comparative biology of the resistance to vitamin K antagonists: An overview of the resistance mechanisms. InAnticoagulation Therapy 2016 Sep 8 (p. 19). BoD–Books on Demand.

Lasseur R, Longin-Sauvageon C, Videmann B, Billeret M, Berny P, Benoit E. Warfarin resistance in a French strain of rats. J Biochem Mol Toxicol. 2006;19(6): 379–85.

Bevans CG, Krettler C, Reinhart C, Tran H, Koßmann K, Watzka M, et al. Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay. Biochim Biophys Acta BBA – Gen Subj. 2013;1830(8):4202–10.

Thijssen HHW. Warfarin resistance: Vitamin K epoxide reductase of scottish resistance genes is not irreversibly blocked by warfarin. Biochem Pharmacol. 1987;36(17):2753–7.

Grandemange A, Kohn MH, Lasseur R, Longin-Sauvageon C, Berny P, Benoit E. Consequences of the Y139F VKORC1 mutation on resistance to AVKs: In-vivo inves‐ tigation in a 7th generation of congenic Y139F strain of rats. Pharmacogenet Genomics. 2009;19(10):742–50.

Asher G, Dym O, Tsvetkov P, Adler J, Shaul Y. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochem‐ istry (Mosc). 2006;45(20):6372–8.

Hodroge A, Longin-Sauvageon C, Fourel I, Benoit E, Lattard V. Biochemical charac‐ terization of spontaneous mutants of rat VKORC1 involved in the resistance to antivitamin K anticoagulants. Arch Biochem Biophys. 2011;515(1–2):14–20. 38 Anticoagulation Therapy

Czogalla KJ, Biswas A, Wendeln A-C, Westhofen P, Müller CR, Watzka M, et al. Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces. Blood. 2013;122(15):2743–50.

Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hy‐ droxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5(1): 54–9.

Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, et al. Warfarinfluconazole. II. A metabolically based drug interaction: In vivo studies. Drug Metab Dispos. 1996;24(4):422–8.

Takahashi H, Kashima T, Kimura S, Murata N, Takaba T, Iwade K, et al. Pharmacoki‐ netic interaction between warfarin and a uricosuric agent, bucolome: Application of in vitro approaches to predicting in vivo reduction of (s)-warfarin clearance. Drug Metab Dispos. 1999;27(10):1179–86.

Gaio V, Picanço I, Nunes B, Fernandes A, Mendonça F, Horta Correia F, et al. Pharma‐ cogenetic profile of a South Portuguese population: Results from the pilot study of the European Health Examination Survey in Portugal. Public Health Genomics. 2015;18(3): 139–50.

Giri AK, Khan NM, Grover S, Kaur I, Basu A, Tandon N, et al. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacoge‐ nomics. 2014;15(10):1337–54.

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans. Pharmacogenomics. 2008;9(10):1445– 58.

Shahin MHA, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, et al. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost. 2013;109(6):1045–50.

Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the ashkenazi and sephardi jewish populations. Am J Hum Genet. 2008;82(2):495–500.

Sominsky S, Korostishevsky M, Kurnik D, Aklillu E, Cohen Y, Ken-Dror G, et al. The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations. J Appl Genet. 2014;55(2):163–71.

Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. 2011;12(7):953–63.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African–Americans: Implications for pharmacogenetic dosing. Pharmacogenomics. 2009;10(8):1243–55.

Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, et al. Pharma‐ codynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost. 2008;6(10):1663–70.

Fregin A, Czogalla KJ, Gansler J, Rost S, Taverna M, Watzka M, et al. A new cell culturebased assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay. J Thromb Haemost. 2013;11(5):872–80.

Šupe S, Božina N, Matijević V, Bazina A, Mišmaš A, Ljevak J, Alvir D, Habek M, Poljaković Z. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1—Implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the neurological sciences. 2014 Aug 15;343(1-2):30-5.

Nakai K, Tsuboi J, Okabayashi H, Fukuhiro Y, Oka T, Habano W, Fukushima N, Nakai K, Obara W, Fujioka T, Suwabe A. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients.